Active pharmaceutical ingredients (APIs) are frequently delivered to the patients in the solid-state formulation. Yet, therapeutic effectiveness of a dosage form depends on the bioavailability, stability and also on the manufacturability of the dosage form. Crystal engineering is the design and synthesis of molecular solid-state structures with desired properties, based on an understanding and use of intermolecular interactions. Recently, crystal engineering-based pharmaceutical cocrystallisation approach has shown significant promise in attaining desired physicochemical and mechanical properties to the pharmaceutical materials.
Recent findings in the area of pharmaceutical cocrystals demonstrate that it has advanced from an early development (preclinical studies) to marketed drug products, for example, Entresto (valsartan – sacurbitril) by Novartis and Suglat (iproglifozin – L-proline) by Astellas Pharma. There have been considerable advancements in the design and synthesis of pharmaceutical cocrystals thus far. The current PhD project will focus on translational research from molecular to medicines development. To perform this interdisciplinary project, the prospective PhD applicant will work with Pharmaceutical Engineering and Science groups and will be able to learn and utilise pharmaceutical industry relevant technologies.